JUL 22·SEC EDGARLow
Happel David sold $497K of SGMT
Happel David (President & CEO) sold 64,051 shares of Sagimet Biosciences Inc. (SGMT) at $7.76 ($0.50M total) on 2026-07-20.
StockNASDAQ · US · USDHealthcare · Biotechnology
$SGMT
Sagimet Biosciences Inc.
Price · $SGMTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $SGMT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $719K 3 txs
Rozek Elizabeth1× · $82K
10b5-1 plan33%
Top stories · $SGMTMore →
JUL 15·yahoo.com
Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion
Sagimet Biosciences (NASDAQ:SGMT) said it was added to the Russell 3000 and Russell 2000 indexes in the 2026 reconstitution, based on April 30 market caps. Inclusion can trigger automatic moves into Russell 1000 or 2000 and related value or growth indexes. CEO David Happel linked the visibility to its planned denifanstat Phase 3 acne study.
JUN 12·SEC EDGAR 8-K
Sagimet Biosciences Inc. (SGMT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Sagimet Biosciences Inc. (SGMT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001400118 0001400118 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
SGMT sentiment & insider activity
Recent SGMT coverage spans financial news, corporate actions and insider activity.
In the last 30 days, SGMT insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($719K). The most active reporter was Rozek Elizabeth, Chief Legal & Admin. Officer, with 1 filing. 33% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving SGMT
This is a routine insider sale disclosure with no stated 10b5-1 plan, but it does not provide new fundamentals or guidance.
Index inclusion can drive mechanical ETF and index-fund buying, while the article also ties it to anticipated Phase 3 momentum for denifanstat.
Board turnover plus finalized shareholder voting outcomes may affect governance perception, but the filing states the resignation was due to other commitments (no dispute).
Sagimet Biosciences' participation in a prominent healthcare conference may enhance investor confidence and visibility, potentially leading to short-term positive price movement.
The company's participation in a prominent healthcare conference signals ongoing investor interest and potential positive developments.
alphai scores every news story that mentions SGMT with an AI model for sentiment and relevance, and aggregates insider trades from Sagimet Biosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $SGMT
Score
Happel David sold $497K of SGMT
Happel David (President & CEO) sold 64,051 shares of Sagimet Biosciences Inc. (SGMT) at $7.76 ($0.50M total) on 2026-07-20.
1 min readSagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion
Sagimet Biosciences (NASDAQ:SGMT) said it was added to the Russell 3000 and Russell 2000 indexes in the 2026 reconstitution, based on April 30 market caps. Inclusion can trigger automatic moves into Russell 1000 or 2000 and related value or growth indexes. CEO David Happel linked the visibility to its planned denifanstat Phase 3 acne study.
3 min readSagimet Biosciences Inc. (SGMT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Sagimet Biosciences Inc. (SGMT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001400118 0001400118 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readSagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
SAN MATEO, Calif., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( Nasdaq: SGMT ) , a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the 8th Annual ...
2 min read
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - Sagimet Biosciences (NASDAQ:SGMT)
SAN MATEO, Calif., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( NASDAQ:SGMT ) , a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the 8th Annual ...
3 min read
All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy
Sagimet Biosciences Inc. (SGMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2 min read
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis - Sagimet Biosciences (NASDAQ:SGMT)
Denifanstat met all primary and secondary endpoints versus placebo Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in acne SAN MATEO, Calif., Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc.
3 min read
Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
3 min readSagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - Sagimet Biosciences (NASDAQ:SGMT)
SAN MATEO, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( ( Sagimet, NASDAQ:SGMT ) , a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will give two oral ...
2 min read
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 min read